STAT

Opinion: After amyloid failures, it’s time to take a new tack for treating Alzheimer’s

The amyloid cabal and groupthink kept other ideas for #Alzheimers treatments from being developed. Now that the insanity of that approach is behind us, it's time to make real progress…

If insanity is doing the same thing over and over again but expecting different results, then the last decade or so of Alzheimer’s disease drug development has been insane. Three carefully designed, well-executed, and fully resourced trials targeting amyloid protein in the brain as the cause of Alzheimer’s disease have failed. It’s long past time to take a new approach to this mind-robbing disease.

In 1906, psychiatrist Alois Alzheimer of a 50-year-old woman he had followed for five years, from her admission to a psychiatric hospital for paranoia, progressive sleep and memory disturbance, aggression, and confusion until her death. His autopsy of her brain revealed unusual plaques of amyloid and tangles of neurofibrils. Three years later he described three more cases, including one individual whose brain showed only

You're reading a preview, sign up to read more.

More from STAT

STAT7 min readPolitics
Inhumane Or Unavoidable? As Congress Scrutinizes An Increase In Monkey Research, Scientists Defend Its Necessity
Scientists are relying on monkey research more than ever before. And now Congress wants the NIH and FDA to explain why.
STAT6 min readSociety
Opinion: Combatting Misinformation On Biosimilars And Preparing The Market For Them Can Save The U.S. Billions
For more than a decade, biosimilars have flourished in Europe. That hasn't happened in the U.S. because of misinformation and poor market preparation.
STAT3 min readPolitics
With Eyes On Gilead, Lawmakers Want Details On How HHS Reviews Possible Patent Infringement
After a ruckus over a pricey Gilead Sciences drug for HIV, lawmakers want details on how HHS reviews possible patent infringement.